These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 33725321)

  • 21. Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison.
    Fautrel B; Zhu B; Taylor PC; van de Laar M; Emery P; De Leonardis F; Kannowski CL; Nicolay C; Kadziola Z; De La Torre I; Fleischmann R
    RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
    Wei D; Chen Y; Shen Y; Xie B; Song X
    Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis.
    Bergrath E; Gerber RA; Gruben D; Lukic T; Makin C; Wallenstein G
    Int J Rheumatol; 2017; 2017():8417249. PubMed ID: 28377787
    [No Abstract]   [Full Text] [Related]  

  • 24. Relative remission rates of Janus kinase inhibitors in comparison with adalimumab in patients with active rheumatoid arthritis: a network meta-analysis.
    Lee YH; Song GG
    Z Rheumatol; 2024 Feb; 83(Suppl 1):88-96. PubMed ID: 35142908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.
    Tanaka Y; Emoto K; Cai Z; Aoki T; Schlichting D; Rooney T; Macias W
    J Rheumatol; 2016 Mar; 43(3):504-11. PubMed ID: 26834213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Network meta-analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis.
    Li Y; Yao C; Xiong Q; Xie F; Luo L; Li T; Feng P
    J Clin Pharm Ther; 2022 Jul; 47(7):851-859. PubMed ID: 35253941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors.
    Kitanaga Y; Imamura E; Nakahara Y; Fukahori H; Fujii Y; Kubo S; Nakayamada S; Tanaka Y
    Rheumatology (Oxford); 2020 Aug; 59(8):1957-1968. PubMed ID: 31764973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effects of peficitinib and tofacitinib in the adjuvant-induced arthritis rat model.
    Ishikawa G; Kwon C; Fujii Y
    Eur J Pharmacol; 2023 Feb; 941():175490. PubMed ID: 36608862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
    Tanaka Y; Takeuchi T; Tanaka S; Kawakami A; Iwasaki M; Song YW; Chen YH; Wei JC; Lee SH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Akazawa R; Shiomi T; Yamada E
    Ann Rheum Dis; 2019 Oct; 78(10):1320-1332. PubMed ID: 31350270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
    van der Heijde D; Strand V; Tanaka Y; Keystone E; Kremer J; Zerbini CAF; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Gruben D; Wallenstein G; Connell CA; Fleischmann R;
    Arthritis Rheumatol; 2019 Jun; 71(6):878-891. PubMed ID: 30666826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.
    Strand V; Ahadieh S; French J; Geier J; Krishnaswami S; Menon S; Checchio T; Tensfeldt TG; Hoffman E; Riese R; Boy M; Gómez-Reino JJ
    Arthritis Res Ther; 2015 Dec; 17():362. PubMed ID: 26669566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
    Kunwar S; Collins CE; Constantinescu F
    Clin Rheumatol; 2018 Oct; 37(10):2611-2620. PubMed ID: 30006916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
    Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
    Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.
    Kivitz AJ; Gutierrez-Ureña SR; Poiley J; Genovese MC; Kristy R; Shay K; Wang X; Garg JP; Zubrzycka-Sienkiewicz A
    Arthritis Rheumatol; 2017 Apr; 69(4):709-719. PubMed ID: 27748083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan.
    Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Song YW; Chen YH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y
    Rheumatol Ther; 2021 Mar; 8(1):425-442. PubMed ID: 33656739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the efficacy and safety of sarilumab combination therapy in patients with rheumatoid arthritis with inadequate response to conventional disease-modifying antirheumatic drugs or tumour necrosis factor α inhibitors: systematic literature review and network meta-analyses.
    Choy E; Freemantle N; Proudfoot C; Chen CI; Pollissard L; Kuznik A; Van Hoogstraten H; Mangan E; Carita P; Huynh TM
    RMD Open; 2019; 5(1):e000798. PubMed ID: 30886733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase.
    Vallejo-Yagüe E; Weiler S; Micheroli R; Burden AM
    Drug Saf; 2020 Sep; 43(9):881-891. PubMed ID: 32533433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.
    Huang F; Luo ZC
    Clin Rheumatol; 2019 Feb; 38(2):523-534. PubMed ID: 30242639
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of Adverse Drug Events Observed with Baricitinib 2 mg Versus Baricitinib 4 mg Once Daily for the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Huang F; Luo ZC
    BioDrugs; 2018 Oct; 32(5):415-423. PubMed ID: 30203252
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.
    Takeuchi T; Tanaka Y; Iwasaki M; Ishikura H; Saeki S; Kaneko Y
    Ann Rheum Dis; 2016 Jun; 75(6):1057-64. PubMed ID: 26672064
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.